NPCE enters 2026 with rising RNS adoption, stronger margins and Medicare payment hikes that could boost hospital economics for replacement procedures.

NPCE's Seizure ID AI tool and potential idiopathic generalized epilepsy approval could expand RNS adoption as NeuroPace pushes software-driven care in 2026.

Consultant Psychiatrist and Chief Executive Officer of the Mental Health Authority Dr Eugene Dordoye, has emphasised that epilepsy is a neurological condition, not a mental health disorder, in a bid ...

The company reiterated "full year 2026 revenue guidance of $98 million to $100 million," assuming "underlying core RNS growth of 20% to 22% within our current adult focal epilepsy indication and ...

Now the following is merely a personal theory; I put it out there for your consideration and discussion and not in any way as ...

Tele Vet Neil McIntosh tests his theory of why people - including veterinary surgeons - might sometimes be guilty of having ...

For Anne Morman, March 18 is a day of remembrance. On what would have been her daughter, Ashley Russell’s birthday, an annual blood drive is now held in her honor.

The company finished 2025 with a convincing pair of earnings beats.

"I was in hospital once and about to be put under sedation. I casually asked how anesthesia works, to which the anesthetist ...

NeuroPace Inc (NPCE) reports robust revenue growth and positive EBITDA, while navigating challenges and advancing its AI-driven product pipeline.

Nia Therapeutics announced today that it received FDA breakthrough device designation for its Smart Neurostimulation System (SNS).

Work through the questions and explanations to build confidence in providing safe, patient-centred emergency contraception.